1.Intra-nucleus accumbens shell injection of baclofen blocks the reconsolidation of conditioned place preference in morphine-addicted mice.
Ruo-Chen WANG ; Li-Fei XIAO ; Chun ZHANG ; Tao SUN ; Kui-Sheng SUN
Acta Physiologica Sinica 2020;72(2):255-261
Preclinical studies suggest that the GABA receptor is a potential target for treatment of substance use disorders. Baclofen (BLF), a prototypical GABA receptor agonist, is the only specific GABA receptor agonist available for application in clinical addiction treatment. The nucleus accumbens shell (AcbSh) is a key node in the circuit that controls reward-directed behavior. However, the relationship between GABA receptors in the AcbSh and memory reconsolidation was unclear. The aim of this study was to investigate the effect of intra-AcbSh injection of BLF on the reconsolidation of morphine reward memory. Male C57BL/6J mice were used to establish morphine conditioned place preference (CPP) model and carry out morphine reward memory retrieval and activation experiment. The effects of intra-AcbSh injection of BLF on morphine-induced CPP, reinstatement of CPP and locomotor activity were observed after environmental cues activating morphine reward memory. The results showed that intra-AcbSh injection of BLF (0.06 nmol/0.2 μL/side or 0.12 nmol/0.2 μL/side), rather than vehicle or BLF (0.01 nmol/0.2 μL/side), following morphine reward memory retrieval abolished morphine-induced CPP by disrupting its reconsolidation in mice. Moreover, this effect persisted for more than 14 days, which was not reversed by a morphine priming injection. Furthermore, intra-AcbSh injection of BLF without morphine reward memory retrieval had no effect on morphine-associated reward memory. Interestingly, administration of BLF into the AcbSh had no effect on the locomotor activity of mice during testing phase. Based on these results, we concluded that intra-AcbSh injection of BLF following morphine reward memory could erase morphine-induced CPP by disrupting its reconsolidation. Activating GABA receptor in AcbSh during drug memory reconsolidation may be a potential approach to prevent drug relapse.
Animals
;
Baclofen
;
administration & dosage
;
Conditioning, Classical
;
GABA-B Receptor Agonists
;
administration & dosage
;
Locomotion
;
Male
;
Memory
;
Mice
;
Mice, Inbred C57BL
;
Morphine
;
Nucleus Accumbens
;
drug effects
;
Opioid-Related Disorders
;
Reward
2.The influence of GABAA receptor on the analgesic action of intrathecally injected oxysophoridine.
Guang YANG ; Jin-xian GAO ; Zheng-hong YI ; Lin YAN ; Yuan-Xu JIANG
Acta Pharmaceutica Sinica 2011;46(5):534-538
.This study is to investigate the analgesic effect produced by intrathecal injection (ith) of oxysophoridine (OSR) and the mechanism of GABAA receptor. Warm water tail-flick test was used to detect the analgesic effect of OSR (12.5, 6.25, and 3.13 mg.kg-1 ith) and to observe the influence of GABA (gamma aminobutyric acid) agonist or antagonist on the analgesic effect of OSR in mice. Immunohistochemistry method were used to detect the influence of OSR (12.5 mg.kg-1, ith) on the GABAARalpha1 protein expression in spinal cord. The results obtained covers that OSR (12.5 and 6.25 mg.kg-, ith) alleviates pain significantly with the warm water tail-flick test (P<0.05, P<0.01), the rate of pain threshold increases by 68.45%; GABA and muscimol (MUS) produces analgesic synergism together with the OSR, picrotoxin (PTX) and bicuculline (BIC) antagonize the analgesic effect of OSR; OSR (12.5 mg.kg-1, ith) significantly increase the positive number of GABAARalpha1 nerve cell in spinal cord (P<0.01) and significantly decrease the average grey levels (P<0.01). In conclusion, OSR intrathecal injection has significant analgesic effect. And GABAA receptor in spinal cord is involved in the analgesic mechanism.
Alkaloids
;
administration & dosage
;
pharmacology
;
Analgesics
;
administration & dosage
;
pharmacology
;
Animals
;
Bicuculline
;
pharmacology
;
Female
;
GABA-A Receptor Agonists
;
pharmacology
;
GABA-A Receptor Antagonists
;
pharmacology
;
Injections, Spinal
;
Male
;
Mice
;
Muscimol
;
pharmacology
;
Pain Threshold
;
drug effects
;
Picrotoxin
;
pharmacology
;
Random Allocation
;
Receptors, GABA-A
;
metabolism
;
Spinal Cord
;
metabolism
;
gamma-Aminobutyric Acid
;
pharmacology
3.Pharmacology of Intracisternal or Intrathecal Glycine, Muscimol, and Baclofen in Strychnine-induced Thermal Hyperalgesia of Mice.
Il Ok LEE ; Jin Kook SON ; Eui Sung LIM ; Yeon Soo KIM
Journal of Korean Medical Science 2011;26(10):1371-1377
Glycine and gamma-aminobutyric acid (GABA) are localized and released by the same interneurons in the spinal cord. Although the effects of glycine and GABA on analgesia are well known, little is known about the effect of GABA in strychnine-induced hyperalgesia. To investigate the effect of GABA and the role of the glycine receptor in thermal hyperalgesia, we designed an experiment involving the injection of muscimol (a GABAA receptor agonist), baclofen (a GABAB receptor agonist) or glycine with strychnine (strychnine sensitive glycine receptor antagonist). Glycine, muscimol, or baclofen with strychnine was injected into the cisterna magna or lumbar subarachnoidal spaces of mice. The effects of treatment on strychnine-induced heat hyperalgesia were observed using the pain threshold index via the hot plate test. The dosages of experimental drugs and strychnine we chose had no effects on motor behavior in conscious mice. Intracisternal or intrathecal administration of strychnine produced thermal hyperalgesia in mice. Glycine antagonize the effects of strychnine, whereas, muscimol or baclofen does not. Our results indicate that glycine has anti-thermal hyperalgesic properties in vivo; and GABA receptor agonists may lack the binding abilities of glycine receptor antagonists with their sites in the central nervous system.
Animals
;
Baclofen/*administration & dosage/pharmacology
;
Drug Delivery Systems
;
GABA Agonists/administration & dosage/pharmacology
;
GABA Antagonists/administration & dosage/pharmacology
;
Glycine/*administration & dosage/pharmacology
;
Hot Temperature
;
Hyperalgesia/chemically induced/*drug therapy
;
Injections, Spinal
;
Male
;
Mice
;
Mice, Inbred ICR
;
Muscimol/*administration & dosage/pharmacology
;
Pain Threshold
;
Random Allocation
;
Strychnine
;
gamma-Aminobutyric Acid/metabolism
4.Spinal Gabapentin and Antinociception: Mechanisms of Action.
Myung Ha YOON ; Jeong Il CHOI ; Seong Wook JEONG
Journal of Korean Medical Science 2003;18(2):255-261
Spinal gabapentin has been known to show the antinociceptive effect. Although several assumptions have been suggested, mechanisms of action of gabapentin have not been clearly established. The present study was undertaken to examine the action mechanisms of gabapentin at the spinal level. Male SD rats were prepared for intrathecal catheterization. The effect of gabapentin was assessed in the formalin test. After pretreatment with many classes of drugs, changes of effect of gabapentin were examined. General behaviors were also observed. Intrathecal gabapentin produced a suppression of the phase 2 flinching, but not phase 1 in the formalin test. The antinociceptive action of intrathecal gabapentin was reversed by intrathecal NMDA, AMPA, D-serine, CGS 15943, atropine, and naloxone. No antagonism was seen following administration of bicuculline, saclofen, prazosin, yohimbine, mecamylamine, L-leucine, dihydroergocristine, or thapsigargin. Taken together, intrathecal gabapentin attenuated only the facilitated state. At the spinal level, NMDA receptor, AMPA receptor, nonstrychnine site of NMDA receptor, adenosine receptor, muscarinic receptor, and opioid receptor may be involved in the antinociception of gabapentin, but GABA receptor, L-amino acid transporter, adrenergic receptor, nicotinic receptor, serotonin receptor, or calcium may not be involved.
Acetic Acids/administration & dosage
;
Acetic Acids/metabolism
;
Acetic Acids/pharmacology*
;
Adrenergic Antagonists/metabolism
;
Adrenergic alpha-Antagonists/metabolism
;
Analgesics/administration & dosage
;
Analgesics/metabolism
;
Analgesics/pharmacology*
;
Animals
;
Atropine/metabolism
;
Dihydroergocristine/metabolism
;
Enzyme Inhibitors/metabolism
;
Excitatory Amino Acid Agonists/metabolism
;
GABA Antagonists/metabolism
;
Injections, Spinal
;
Leucine/metabolism
;
Male
;
Mecamylamine/metabolism
;
Muscarinic Antagonists/metabolism
;
N-Methylaspartate/metabolism
;
Naloxone/metabolism
;
Narcotic Antagonists/metabolism
;
Nicotinic Antagonists/metabolism
;
Pain Measurement
;
Quinazolines/metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Serine/metabolism
;
Spinal Cord/drug effects*
;
Thapsigargin/metabolism
;
Triazoles/metabolism
;
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/metabolism